


9<sup>th</sup> World Conference



# TARGETING Phage Therapy

JUNE 9 · 10 2026  
VALENCIA · SPAIN



PROGRAM

PHAGE  
THERAPY  
2026

# 9<sup>th</sup> World Congress Targeting Phage Therapy 2026

June 9 - 10, 2026 – Valencia, Spain

## Day 1 - June 9, 2026

8h00 Welcoming of attendees & Badge Distribution

8h50 Opening Remarks by Sandra Sevilla, President, CECAV, Spain & Marvin Edeas, Founder of Phage Therapy

### 9h00 **Keynote Speech**



**Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections**  
*Benjamin K. Chan, Yale University, USA*

## Session 1 – Advances in Phage Therapy: From Mechanisms to Clinical Translation

*Chairs: Marvin Edeas, Sandra Sevilla*



9h45 **Advancing Phage Therapy for Chronic Infections:  
From Experimental Evidence to Clinical Use**  
*Joana Azeredo, University of Minho, Portugal*



10h15 **Bacteriophages Redesigned: Engineering of Next-Generation  
Phage Therapeutics and Diagnostics**  
*Martin J. Loessner, ETH Zürich, Switzerland*

### 10h45 Coffee Break, Networking and Poster Sessions



11h30 **Shaping Phage Susceptibility Landscapes for Personalized Therapy**  
*Katrine Whiteson, UC Irvine, USA (Online)*

12h00 Short Oral presentations

**Phage–antibiotic synergy re-sensitizes MDR Klebsiella biofilms and suppresses resistance**  
*Tinatini Tchatchiashvili, Jena University Hospital, Germany*

12h10 Discussion

### 12h30 Lunch Break, Networking, Group Photo

**PHAGE**  
THERAPY 2026

## Session 2 – Phages Across One Health: Animal, Food, and Industry

*Chairs: Pilar Garcia, Pablo Catalá Gregori*



14h00 **Phage for Sustainable and Scalable Infection Control in Aquaculture**  
**Adelaide Almeida**, Universidade de Aveiro, Portugal



14h30 **Phage Therapy in Livestock Disease Models: Lessons for Animal and Human Health**  
**Robert Atterbury**, University of Nottingham, United Kingdom



15h00 **Nasopharyngeal Phages: The Silent Players in Piglet Health**  
**Oscar Mencía-Ares**, Universidad de León, Spain

**15h30 Coffee Break, Networking, Poster Presentation**

16h15 Short Oral presentations (10 Minutes)

*Chairs: Annika Y. Classen, Danish J. Malik*

**Investigating Phage-Antibiotic Synergy Against Multidrug-Resistant Infections**  
**Emma Kane**, Yale University, USA

**Genomic indicators of bacteriophage susceptibility in ESBL-producing uropathogenic E. coli**  
**Debra Satie Nagano**, Kyorin University, Japan

**Intravenous versus intravenous and inhaled delivery of bacteriophages: Pharmacokinetics and pharmacodynamics in pigs with or without ventilator-associated pneumonia**  
**Viviane Oliveira**, CIBER, Spain

**Nucleotide Derivatives Activate Abortive Infection During Bacterial Antiphage Defense**  
**Giedrius Sasnauskas**, Vilnius University, Lithuania

**In Vitro Assessment of Lytic Bacteriophage Specificity toward Pathogens and Probiotic Bacteria**  
**Nicola Mangieri**, University of Milan, Italy

**Inhibition of a Bacterial Antiviral System by Chemical Compounds**  
**Dziugas Sabonis**, Vilnius University, Lithuania

17h15 Poster Flash Session (3 Minutes)

**Large-Scale Mutagenesis of the T7 RBP Enables Infection of Otherwise Resistant Escherichia Coli Hosts**  
**Constantinos Patinios**, VU LSC-EMBL Partnership Institute, Lithuania

**A Comprehensive Analysis of the Kinetics of Infection of Lytic Bacteriophages Specific to the Escape and Critical Pathogens**

**Olaf Bajrak**, Hirszfeld's Institute of Immunology and Experimental Therapy, Poland

**Formulation, Characterization, and Biofilm Eradication Efficacy of Liposome-Encapsulated Bacteriophages Against Salmonella**

**Manana Loladze**, Eliava institute of Bacteriophages, Georgia

**Modeling Pseudomonas aeruginosa biofilm and phage therapy in a cystic fibrosis ex vivo pig lung model**

**Marco Cafora**, University of Milan, Italy

**One Health Phage Library-CSIC**

**Pilar García**, CSIC, Spain

**Pseudomonas Aeruginosa Dev Phage Exploits the Essential Lptd Outer Membrane Protein as Receptor for Adsorption**

**Jimena Nieto**, University of Milan, Italy

**Synergistic Antibacterial and Antibiofilm Effect of Bacteriophage K14 in Combination with Antibiotics against Klebsiella pneumoniae**

**Damla Damar Celik**, Marmara University, Turkey

**Isolation And Characterization of Bacteriophages Against Multidrug-Resistant Enterococcus Faecalis from Poultry**

**Josep García-Llorens**, CECAV, Spain

**Phage-Based Control of Salmonella Infantis in Poultry Systems**

**Jan Torres-Boncompte**, CECAV, Spain

17h45 End of Conference Day One

20h30 Speakers' Dinner (Reserved for ticket holders) – Register on the website

## Day 2 - June 10, 2026

8h55 Welcoming of attendees

### Session 3 – Production, Regulation, and Market Access

*Chairs: Benjamin K. Chan, Joana Azeredo*



9h00 **Personalized Bacteriophage Therapy in Germany and Beyond – A Consensus-Based Guideline**  
*Annika Y. Classen, Cologne University Hospital, Germany*



9h30 **France launches its first public GMP Platform to produce large batches of Therapeutic Phages at affordable scale**  
*Frédéric Laurent, Hospices Civils de Lyon, France*

10h00 Discussion

10h10 Short Oral presentations (10 Minutes)

**Modular Platform for Efficient Phage Purification**  
*Isabel Marie Nowak, Technische Hochschule Mittelhessen, Germany*

**The EU legal framework for one-size-fits-all versus personalized phage therapy**  
*Timo Faltus, Martin-Luther-University Halle-Wittenberg, Germany*

**10h30 Coffee Break, Networking and Poster Sessions**



11h15 **The Qualified Presumption of Safety (QPS) Qualification of Lytic Bacteriophages: Scientific Criteria and Regulatory Perspectives**  
*Juan Evaristo Suárez, Universidad de Oviedo, Spain*



11h45 **From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages**  
*Danish J. Malik, Loughborough University, United Kingdom*

12h15 Poster Flash Session (3 Minutes)

**Engineering Safer Bacterial Hosts For Gmp Production Of Therapeutic Bacteriophages**  
*Martin Benesik, Masaryk University/MB Pharma, Czech Republic*

**Clinical Development of Duofag® for Complicated Wound Infections**  
*Dana Kocourková, MB Pharma s.r.o., Czech Republic*

**What the Phage 2.0: A Platform for Pre-Clinical Phage Characterization**  
*Mike Marquet, University Hospital Jena, Germany*

**Isolation and Characterization of Lytic Bacteriophages Targeting Clinical Multidrug-Resistant Staphylococcus spp. as Therapeutic Candidates**  
*María Ángeles Tormo Mas, Fundación para la Investigación del Hospital La Fe, Spain*

**Crono-Safe: A Targeted Thermostable Bacteriophage Cocktail Against Cronobacter Spp. With Translational Phage Therapy Potential**  
*Michal Kajsik, Comenius University Science Park, Slovak Republic*

**Development of Phage Endolysin-Integrated PH-Responsive Antiadhesive and Antibacterial Coatings with Nanorods for Prevention of Cross-Contamination in Fresh Produce**

**Hui Shi**, Southwest University, China

**Successful Phage Therapy of a Pseudomonas Aeruginosa-Induced Bilateral Otitis Media**

**Miriam Waizer**, University Hospital Regensburg, Germany

**Operationalizing Clinical Phage Therapy Within a National Regulatory Framework: The Eliava Phage Therapy Center (EPTC) Model**

**Mariam Dadiani**, Eliava Phage Therapy Center, Georgia

**12h30 Lunch Break, Networking and Poster**

## Session 4 – Innovation Forum: Building the Future of Phage Therapy

*Chairs: Frédéric Laurent, Martin J. Loessner & Evgenii Rubalskii*



13h30

**Chronic Respiratory Infections in the Inflamed Lung: Host–Pathogen Interactions and Opportunities for Phage Therapeutics**

**Paula Zamora**, University of Kansas Medical Center, USA



14h00

**Phage–Pseudomonas Interactions: Changes in Host Physiology and the Potential Impact on Phage Therapy**

**Piotr Golec**, University of Warsaw, Poland



14h30

**Personalized Phage Therapy at the Hannover Medical School: Barriers, Challenges, and Next Steps**

**Evgenii Rubalskii**, Medizinische Hochschule Hannover, Germany

15h00

**Innovation Forum: From Scientific Concepts to Translational Impact**

**Adaptive Targeting: A High-Throughput Screening Strategy to Overcome Evolved Bacterial Resistance in Phage Therapy**

**Biswajit Biswas**, US Navy, USA

**Engineering Bacteriophages for Targeted Cancer Therapy**

**Henrique G. Ribeiro**, LXbio Pharmaceuticals, Portugal

**E. Coli Bacteriophages: A Natural Alternative for Managing Neonatal Diarrhea in Swine**

**Javier Quero**, Exopol S.L., Spain

**Phage-Derived Receptor-Binding Proteins for Precision Detection and Targeted Control of Carbapenem-Resistant *Klebsiella pneumoniae***

**Silvio Santos**, Universidade do Minho, Portugal

**Virus-Like Particle and Other Protein Therapeutic Functionalization Using the Connectase Platform**

**Constantinos Patinios**, Connectase, Lithuania

**Biohybrids Composed of PRF and GELs with Antibacterial Phages for Controlled Therapeutic Delivery in Infected Wounds**

**Farzaneh Moghtader**, TiPhage, Turkey



16h00 **Roundtable Discussion: Targeting Phage Therapy Beyond 2026: From Promise to Clinical Reality**  
Chaired by Pilar Domingo-Calap, Institute of Integrative Systems Biology, Spain

With insights from: Benjamin K. Chan, Robert Atterbury, Frédéric Laurent, Barbara Brenner, and invited experts.

16h45 Concluding Note & Key Takeaways

16h55 Closing Remarks & Awards by Sandra Sevilla and Marvin Edeas  
Targeting Phage Therapy 2026 Chairs

**17h00 Drinks and Appetizer – Networking**

17h15 **End of Targeting Phage Therapy 2026**

**Thanks to all of our Speakers**



**KEYNOTE**

**Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections**  
Benjamin K. Chan, Yale University, USA



**Advancing Phage Therapy for Chronic Infections: From Experimental Evidence to Clinical Use**  
Joana Azeredo, University of Minho, Portugal



**Bacteriophages Redesigned: Engineering of Next-Generation Phage Therapeutics and Diagnostics**  
Martin J. Loessner, ETH Zürich, Switzerland



**Shaping Phage Susceptibility Landscapes for Personalized Therapy**  
Katrine Whiteson, UC Irvine, USA (Online)



**Phage for Sustainable and Scalable Infection Control in Aquaculture**  
Adelaide Almeida, Universidade de Aveiro, Portugal



**Phage Therapy in Livestock Disease Models: Lessons for Animal and Human Health**  
Robert Atterbury, University of Nottingham, UK



**Nasopharyngeal Phages: The Silent Players in Piglet Health**  
Oscar Mencía-Ares, Universidad de León, Spain



**Roundtable Discussion: Targeting Phage Therapy Beyond 2026: From Promise to Clinical Reality**  
Pilar Domingo-Calap, Institute of Integrative Systems Biology, Spain



**Personalized Bacteriophage Therapy in Germany and Beyond – A Consensus-Based Guideline**  
Annika Y. Classen, Cologne University Hospital, Germany



**France launches its first public GMP Platform to produce large batches of Therapeutic Phages at affordable scale**  
Frédéric Laurent, Hospices Civils de Lyon, France



**The Qualified Presumption of Safety (QPS) Qualification of Lytic Bacteriophages: Scientific Criteria and Regulatory Perspectives**  
Juan Evaristo Suárez, Universidad de Oviedo, Spain



**From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages**  
Danish J. Malik, Loughborough University, UK



**Chronic Respiratory Infections in the Inflamed Lung: Host-Pathogen Interactions and Opportunities for Phage Therapeutics**  
Paula Zamora, University of Kansas Medical Center, USA



**Phage-Pseudomonas Interactions: Changes in Host Physiology and the Potential Impact on Phage Therapy**  
Piotr Golec, University of Warsaw, Poland



**Personalized Phage Therapy at the Hannover Medical School: Barriers, Challenges, and Next Steps**  
Evgenii Rubalskii, Medizinische Hochschule Hannover, Germany

**PHAGE  
THERAPY 2026**

# TARGETING MICROBIOTA

SEPT. 24 > 25 2026 > TOKYO



PROGRAM